Serafin Andrew
Known title: CHIEF STRATEGY OFFICERCIK: 0001821460
Associated companies
Transaction History
| HRMY | ▲ Buy | Option Exercise | 2,600 | $0 | 1/25/2026 | View on chart |
| HRMY | ▼ Sell | Tax Withholding | 1,126 | $41K | 1/25/2026 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 2,500 | $0 | 1/24/2026 | View on chart |
| HRMY | ▼ Sell | Tax Withholding | 1,116 | $41K | 1/24/2026 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 2,500 | $0 | 1/24/2025 | View on chart |
| HRMY | ▼ Sell | Tax Withholding | 865 | $33K | 1/24/2025 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 38,000 | $312K | 12/2/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 37,080 | $2.2M | 12/2/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 920 | $56K | 12/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
HRMY Reports New Phase 3 Data and Maintains Positive Analyst Outlook
HRMY shared new Phase 3 data at the European Narcolepsy Days, adding to its pipeline. Analysts remain upbeat, with Needham keeping a positive stance and a $50 target. The Wakix franchise also offers multiple value drivers. Shares rose 48% recently, yet the stock still trades below its 52‑week low.
HRMY Reports New Phase 3 Data and Maintains Positive Analyst Outlook. HRMY shared new Phase 3 data at the European Narcolepsy Days, adding to its pipeline. Analysts remain upbeat, with Needham keeping a positive stance and a $50 target. The Wakix franchise also offers multiple value drivers. Shares rose 48% recently, yet the stock still trades below its 52‑week low.